baber/WOPTO huggingface dataset:
Patent JP-2911004-B2 (JP)
IPC: H04B10/43
Filed: 1989-10-16
Granted: 1999-06-23
Abstract: A receiver for use in a remote control system in which clock pulse-modulated information pulses are transmitted in a wireless mode to the receiver, the receiver being intended for use in hearing aids in which supply voltages of approximately 1 V are used. This receiver includes a receiving circuit (1) for the conversion of the wirelessly transmitted information pulses into an electric signal, a cascade arrangement of first and second selective amplifier circuits (2) and (4), respectively which each have their highest gain factor at a frequency which is approximately equal to the frequency of the clock pulses. This cascade arrangement is connected to the output of the receiver circuit and supplies a first output signal which is applied to a mean value detector (5) which produces a rough version of the information pulses which are shaped in a pulse shaper (6).
Patent JP-3263051-B2 (JP)
IPC: G01N33/70
Filed: 1999-09-27
Granted: 2002-03-04
Abstract: Disclosed is an improvement to the assay for creatinine in fluid test samples by contacting the test sample with a reagent formulation containing cupric ions, a hydroperoxide and an oxidizable dye. The improvement involves the inclusion of one or more selected quinolines in the reagent formulation. When the quinoline is substituted with methyl in the 2-5 position and/or a methoxy in the 2-6 position autooxidation of the oxidizable dye is reduced. When the quinoline is further substituted in an otherwise unsubstituted carbon atom in the 2-8 position, the assay's resistance to interference from hemoglobin and ascorbate is increased.
Patent JP-4141546-B2 (JP)
IPC: A47L9/19
Filed: 1998-10-02
Granted: 2008-08-27
Abstract: The invention is directed to a method and a circuit arrangement for determining the quantity of the material cut by an electrically powered cutting tool. According to the present invention, the fluctuations of the current consumed by a drive motor are detected, filtered and evaluated. By a comparison with a reference value, it is possible to determine the soiling of the cutting tool with cut residues. The invention is particularly suitable for use in shaving apparatus.
Patent JP-3125101-B2 (JP)
IPC: C07D233/72
Filed: 1991-11-15
Granted: 2001-01-15
Abstract: PCT No. PCT/FR91/00906 Sec. 371 Date Jul. 21, 1992 Sec. 102(e) Date Jul. 21, 1992 PCT Filed Nov. 15, 1991 PCT Pub. No. WO92/08702 PCT Pub. Date May 29, 1992.Method of resolution of chiral hydantoins of the general formula I    <IMAGE>  (I)  in which: R1 designates a lower alkyl radical comprising 1 to 5 carbon atoms in linear or branched chain, R2 designates a phenyl radical, possibly mono-, di-, or tri-substituted by lower alkyl or alkoxy radicals or halogen atoms, whether identical of different, or a heteroaryl radical containing a ring of 5 to 7 members in which the sole hetero atom is nitrogen, oxygen or sulfur, or else an aralkyl radical the alkyl part of which comprises one or two carbon atoms and the aryl ring is a phenyl group possibly mono-, di- or tri-substituted by radicals which are lower alkyl or alkoxy radicals or halogen atoms, whether identical or different. The hydantoin (I) to be resolved is dissolved in an alcohol or an alkaline solution, and an enantiomer of  alpha -methylbenzyl-amine is added in a defined proportion to the solution obtained, whereupon the diastereoisomeric salt obtained is isolated and treated with an acid solution in order to crystallize the enantiomer of hydantoin (I).
Patent JP-2547053-B2 (JP)
IPC: H04B1/66
Filed: 1987-06-26
Granted: 1996-10-23
Abstract: A broad spectrum optical carrier from a source (l) is divided over at least two paths (4), and the carrier in at least one path (4) is modulated (M1-4) in accordance with information (I1-4). The paths are recombined (6) with delay multiplexing (t1-4). At a distribution point (7), the recombined paths (6) are divided and the modulated carrrier in at least one of the paths is combined in heterodyne detection (at D1-4) with a local oscillator signal (via path 5) having a frequency shifted with respect to the carrier. The local oscillator signal is delayed prior to combination by a delay (t1'-4') corresponding to a delay of the delay multiplexing.
Patent JP-3233632-B2 (JP)
IPC: C07C233/87
Filed: 1992-01-16
Granted: 2001-11-26
Abstract: (2R,3S)- beta -Phenylisoserine, its salts and its preparation by the action of ammonia on (2R,3R)- beta -phenylglycidic acid, and its use for the preparation of taxane derivatives of general formula: <IMAGE> (R = H, COCH3; R1 = C6H5, (CH3)3C-O-).t
Patent JP-2581723-B2 (JP)
IPC: H04L9/00
Filed: 1987-07-09
Granted: 1997-02-12
Abstract: PCT No. PCT/FR87/00272 Sec. 371 Date Mar. 10, 1988 Sec. 102(e) Date Mar. 10, 1988 PCT Filed Jul. 9, 1987 PCT Pub. No. WO88/00743 PCT Pub. Date Jan. 28, 1988.The invention relates to a method for authenticating an external authorizing datum by a portable object, such as a memory card. The authorizing datum (C1) entered into an apparatus (2) is enciphered with a predetermined datum (E) to yield a message (M) which is transmitted to a portable object (1). The object (1) deciphers the message (M), taking into account a reference authorizing datum (C1), in order to retrieve a datum (E'), which must be coherent with the datum (E). The invention applies in particular to the recognition of the carrier code of the owner of a credit card.
Patent JP-2853877-B2 (JP)
IPC: C07K19/00
Filed: 1989-03-24
Granted: 1999-02-03
Abstract: The present invention is directed to protamine-reactive, IgM antibodies, and their uses in prognosis, diagnosis, and therapy. In a specific embodiment, the invention relates to low affinity binding, protamine-reactive serum IgM antibodies. In particular, such antibodies can recognize a sequence comprising four arginyl residues, including a triplet, within a six amino acid residue sequence. Such antibodies may be natural antibodies (i.e., not induced). A low affinity subset of serum protamine-reactive IgM antibodies may be assayed for prognosis or diagnosis of AIDS. Such antibodies are detectable in sera of normal subjects and HIV-infected individuals who subsequently exhibit a significant period of latency, but are absent or deficient in sera of individuals diagnosed with AIDS and sera of HIV infected individuals, who though asymptomatic at the time of the sampling, proceed to AIDS within a relatively short time. The invention provides methods and diagnostic kits for the detection and/or measurement of the low affinity subset of protamine-reactive serum IgM antibodies, for the prognosis and diagnosis of AIDS and other immune system abnormalities.
Patent JP-2863008-B2 (JP)
IPC: A01N63/32
Filed: 1994-07-26
Granted: 1999-03-03
Abstract: A biocontrol composition comprising an antagonistic microorganism and a sugar analog (2-deoxy-D-glucose) gives a level of control superior to that of either component when used alone and comparable to that of synthetic chemical fungicides. The antagonistic microorganism is an isolate of Candida saitoana and has resistance to the fungicidal activity of sugars and sugar analogs.
Patent JP-2691169-B2 (JP)
IPC: H01H31/00
Filed: 1988-11-03
Granted: 1997-12-17
Abstract: PCT No. PCT/DE88/00686 Sec. 371 Date Jan. 9, 1991 Sec. 102(e) Date Jan. 9, 1991 PCT Filed Nov. 3, 1988 PCT Pub. No. WO90/01787 PCT Pub. Date Feb. 22, 1990.A metal-clad, compressed-gas insulated, high-voltage switching station with an insulated grounding switch. In the case of compressed-gas insulated, high-voltage switching stations, insulated grounding switches are also used for applying test voltages. Therefore, provided between the housing and the casing is an insulating ring, within which a conductor is embedded with a terminal lug which contacts the contact pin. In order to improve the insulation, the insulating ring reposes within a metallic ring, which acts as a prop ring and which receives the fixing agents. It is only interrupted by the terminal lug which is provided with an insulating enclosure. The insulating ring is thus largely relieved from mechanical stresses. Insulated grounding switches are used in the case of metal-clad, high-voltage switching stations which are insulated by SF6 compressed gas.
Patent JP-3966557-B2 (JP)
IPC: H04N5/363
Filed: 1996-08-12
Granted: 2007-08-29
Abstract: An image system for converting an optical image of an object guided through an optical system (A1) into an electric signal by an amplification MOS sensor and processing the converted signal. The amplification MOS sensor includes a photoelectric conversion element (62) and an amplification MOS transistor (64) connected to the photoelectric conversion element (62). The sensor also has an output circuit and a noise elimination circuit (26, 28, 30, 32, 41). The output circuit amplifies a signal of the photoelectric conversion element (62) and outputs the amplified signal at a first timing, and outputs noise not relevant to the signal of the photoelectric conversion element (62) at a second timing. The noise elimination circuit has the same impedance as seen from the output circuit at the first and second timings and produces a difference between the outputs of the output circuit at the first timing and the second timing. <IMAGE>
Patent JP-3373204-B2 (JP)
IPC: H01J37/32
Filed: 1992-11-30
Granted: 2003-02-04
Abstract: PCT No. PCT/DE92/01005 Sec. 371 Date Jun. 6, 1994 Sec. 102(e) Date Jun. 6, 1994 PCT Filed Nov. 30, 1992 PCT Pub. No. WO93/11275 PCT Pub. Date Jun. 10, 1993.Apparatus and method for corona-activated chemical vapor deposition. A substrate is positioned in a reaction vessel in all-around spaced relationship from the walls of the vessel. A cage having throughgoing perforations surrounds the substrate and is spaced from the vessel walls and the substrate. A corona discharge is generated along at least an inner surface of the cage by connecting the cage and substrate with a voltage source. A reaction gas mixture is passed through the cage and a coating is formed from the reaction gas mixture on the substrate.
Patent JP-3047120-B2 (JP)
IPC: C12Q1/56
Filed: 1992-04-09
Granted: 2000-05-29
Abstract: An kit for an assay for measuring activated factor VII (factor VIIa) is disclosed which employs a reagent comprising truncated tissue factor (tTF), a soluble mutant form of tissue factor (TF) that retains the cofactor function of TF toward factor VIIa, but does not support the conversion of factor VII to VIIa. As a result, the tTF assay for factor VIIa is free from interference from factor VII in the plasma and is therefore specific for factor VIIa. The assay is much simpler than existing assays, because it is a single-stage clotting assay performed almost identically to a prothrombin time (PT) assay. It is also considerably more sensitive than current assays for factor VIIa in plasma. Since the tTF assay is calibrated against a factor VIIa standard, it yields an absolute concentration of factor VIIa in ng/ml.
Patent JP-2863635-B2 (JP)
IPC: B24D3/06
Filed: 1994-09-23
Granted: 1999-03-03
Abstract: The present invention is a metal bond comprising a filler with a Vickers hardness from about 300 kg/mm2 to about 800 kg/mm2 wherein the Vickers hardness of the filler is maintained above 300 kg/mm2 upon firing of the bond at a temperature above 700 DEG  C. for at least about 10 minutes. The present invention further is an abrasive tool comprising a metal core; an abrasive composition comprising diamond and the above metal bond, bonded to the metal core.
Patent JP-3117217-B2 (JP)
IPC: A61K31/506
Filed: 1993-10-28
Granted: 2000-12-11
Abstract: A method and composition for the treatment of humans infected with HBV that includes the administration of an HBV treatment amount of a  beta -dioxolanyl purine nucleoside of the formula:   <IMAGE>   wherein R is OH, Cl, NH2, or H, or a pharmaceutically acceptable salt or derivative of the compound, optionally in a pharmaceutically acceptable carrier or diluent.
Patent JP-4130996-B2 (JP)
IPC: H04L27/26
Filed: 1997-09-01
Granted: 2008-08-13
Abstract: A multi-carrier transmission system such as a DMT system. Channel information is transmitted between two transceivers using a plurality of sub-carriers modulated with symbols, each of which represents a multiplicity of bits. Each of the transceivers includes a receiver and a transmitter in which a fixed maximum value was determined for the number of bits for each symbol and in which the system is adapted to determine the bit capacity per symbol of each of the plurality of sub-carriers and to increase the number of bits represented by a symbol transmitted over those sub-carriers having a capacity less than a fixed maximum value to the maximum value by the addition of channel coding bits. The fixed maximum value for the number of bits for each symbol may be determined on the basis of the bit capacity of that one of the sub-carriers having the highest theoretical bit capacity may be at least as large as the theoretical bit capacity.
Patent JP-H0667306-B2 (JP)
IPC: A23L13/60
Filed: 1990-10-01
Abstract: PCT No. PCT/DE90/00752 Sec. 371 Date Apr. 2, 1991 Sec. 102(e) Date Apr. 2, 1991 PCT Filed Oct. 1, 1990 PCT Pub. No. WO91/04677 PCT Pub. Date Apr. 18, 1991.A process for producing a lumpy meat emulsion product, in which the starting materials including proteins of predominantly animal origin are processed into a meat emulsion at temperatures below 55 DEG  C. The meat emulsion is forced through a gap between plates of a high speed emulsifier into a process tube and rapidly heated to within the range of approximately 40 DEG  to 75 DEG C. such that relatively rapid coagulation of the emulsion material results.
Patent JP-4113580-B2 (JP)
IPC: C12P19/34
Filed: 1995-02-03
Granted: 2008-07-09
Abstract: A process for the depletion or removal of endotoxins from preparations containing active ingredients designated for therapeutical use which are obtained from natural sources by genetic engineering and/or biotechnology by treatment with chromatographic material wherein said natural sources are lysed, the fractions obtained are optionally centrifuged, filtrated or treated with affinity chromatographic methods; said fractions are preincubated with an aqueous salt solution and detergents, treated with anion exchange material and then washed with another salt solution, and the active ingredients are eluted from the anion exchanger, followed by further purification in a per se known manner.
Patent JP-3795073-B2 (JP)
IPC: A61K38/00
Filed: 1995-03-01
Granted: 2006-07-12
Abstract: PCT No. PCT/GB95/00434 Sec. 371 Date Nov. 11, 1996 Sec. 102(e) Date Nov. 11, 1996 PCT Filed Mar. 1, 1995 PCT Pub. No. WO95/23857 PCT Pub. Date Sep. 8, 1995Albumin, for example human albumin, is expressed and secreted in yeast which has been mutated to lack the yeast aspartyl protease 3 (Yap3p) or its equivalent, thereby reducing the production of a 45 kD albumin fragment. A further reduction is achieved by additionally deleting the Kex2p function. Alternatively, a modified albumin is prepared which is not susceptible to Yap3p cleavage, for example human albumin which is R410A, K413Q and K414Q.
Patent JP-3769025-B2 (JP)
IPC: G08B13/24
Filed: 1997-11-21
Granted: 2006-04-19
Abstract: This invention concerns a process and device for producing anti-theft elements for electronic anti-theft securing of articles. The anti-theft elements are made of at least two layers. The invention also concerns a strip material made using the process. The aim of this invention is to present a simple, economical process, a corresponding device for producing a strip material and a strip material for securing articles electronically which is made by the process. As for the process of this invention, the aim is achieved in that segments of a predetermined length of a second web of material are fed and applied on a first continuous web of material perpendicular to the running direction said first web of material.
Patent JP-4143740-B2 (JP)
IPC: C07D239/40
Filed: 1998-01-08
Granted: 2008-09-03
Abstract: PCT No. PCT/EP98/00074 Sec. 371 Date Dec. 17, 1999 Sec. 102(e) Date Dec. 17, 1999 PCT Filed Jan. 8, 1998 PCT Pub. No. WO98/30549 PCT Pub. Date Jul. 16, 1998A process for preparing substituted pyrimidine derivatives of the general formula (I): in which a [3-(dimethylamino)-2-azaprop-2-en-1-ylidine]dimethylammonium halide is reacted with a substituted acetamide. The compounds of general formula (I) are important intermediate products for pharmaceutical or agrochemical active substances.
Patent JP-3847341-B2 (JP)
IPC: C09D11/10
Filed: 1996-05-03
Granted: 2006-11-22
Abstract: PCT No. PCT/IB96/00479 Sec. 371 Date Jan. 6, 1998 Sec. 102(e) Date Jan. 6, 1998 PCT Filed May 3, 1996 PCT Pub. No. WO96/34923 PCT Pub. Date Nov. 7, 1996A lithographic printing ink contains a lithographic varnish containing an alkali soluble or dispersible binder material which is the reaction product of an acid functional hard resin with a fatty ester oil and/or an alkyd resin.
Patent JP-3447062-B2 (JP)
IPC: G01P15/125
Filed: 1999-03-11
Granted: 2003-09-16
Abstract: Pads 24 and 25 to be bonded to connection members are formed at positions where the pads face electrode extraction holes 4a to 4c. A bonding agent 12 low in wettability for the surfaces of electrodes 1 and 3 is used. The bonding agent 12 and high-wettability material form the surfaces of the pads 24 and 25. This can firmly bond the connection members to the electrodes 1 and 3, and can prevent the electrodes 1 and 3 from short-circuiting. <IMAGE>
Patent ES-2344334-B2 (ES)
Title: Generador de energia mediante la oscilacion y prensado en continuo de un fluido.
Inventor: LIZARRALDE ELBERDIN JUAN
IPC: F03B17/00
Filed: 2010-05-25
Granted: 2011-07-26
Abstract: Generador de energía mediante la oscilación y
prensado de un fluido, que comprende una estructura portante (2) con
rodamientos o poleas (4) para deslizamiento de, al menos, dos cables
(3) a cuyos extremos se sujetan contenedores (5) de fluido asociados
cada uno a una placa prensa (6) inferior que penetra ajustadamente
en un recipiente abierto (7) ubicado debajo también con fluido. Los
contenedores (5) tienen superiormente una válvula de cierre (17)
accionada mediante medios motorizados y cada par de cada cable (3)
está comunicado entre sí mediante una tubería (14) en un primer
circuito cerrado de fluido. 
     Los recipientes abiertos (7) tienen boca de
entrada (8) y de salida (9) de fluido desde y hacia un segundo
circuito de conducciones (10) comunican entre sí las bocas de salida
(9) y conducen el fluido hacia un depósito de almacenamiento (11),
existiendo una turbina (12) para transformar la potencia en energía
eléctrica.
Patent ES-2489390-B2 (ES)
Title: Levadura Torulaspora y su uso para la elaboración de productos fermentados
Inventor: RAMIREZ FERNANDEZ MANUEL
IPC: C12R1/645
Filed: 2013-02-19
Granted: 2015-02-27
Abstract: Levadura Torulaspora y su uso para la elaboración de productos fermentados.#La presente invención pertenece al campo técnico de las fermentaciones industriales, más concretamente, la presente invención se refiere a una levadura del género Toluraspora que pertenece a la especie T. delbrueckii o T. pretoriensis, con capacidad para degradar ácido L-málico y producir ácido L-láctico, caracterizada por los números de depósito CECT13083 y CECT13082, y a su uso para elaborar productos fermentados. Asimismo, se refiere a un procedimiento para elaborar productos fermentados que comprende la fermentación de una materia prima de partida con dicha levadura Toluraspora.
Patent AU-2001292231-B2 (AU)
Title: Derivatives of partially desulphated glycogaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
Inventor: GIANNINI GIUSEPPE
IPC: A61P3/10
Filed: 2001-09-12
Granted: 2008-06-05
Abstract: Totally N-desulphated, N-reacetylated heparin derivatives endowed with antiangiogenic activity and devoid of anticoagulant activity are disclosed.
Patent AU-2002338311-B2 (AU)
Title: A combination dosage of a cyclooxygenase (COX) inhibitor, a vitamin D3 including analogues and metabolites thereof and/or calcium for prevention of epithelial cancer
Inventor: RASKOV HANS HENRIK
IPC: A61K31/00
Filed: 2002-04-05
Granted: 2006-08-10
Abstract: The present invention relates to a method for prevention of epithelial cancer such as lung, bladder, prostate or gynaecological cancer or the initiation and/or progression of epithelial cancer such as lung, bladder, prostate or gynaecological cancer in a human comprising administering to the human of a combination dosage of a cyclooxygenase (COX) inhibitor, a vitamin D3 including analogues and metabolites thereof and/or calcium. In a further aspect the invention relates to a method for reducing the effective dosage of ASA in a chemopreventive treatment of epithelial cancer in a human by co-administration with a non toxic dosage of a vitamin D3 including analogues and metabolites thereof and/or Ca in the form of a combination dosage. In another embodiment the invention relates to the use of a cyclooxygenase (COX) inhibitor, a vitamin D3 including analogues and metabolites thereof and/or calcium for the preparation of a medicament for the prevention of epithelial cancer such as lung, bladder, prostate or gynaecological cancer or the initiation and/or progression of epithelial cancer such as lung, bladder, prostate or gynaecological cancer.
Patent AU-2002340787-B2 (AU)
Title: Peptide purification by means of metal ion affinity chromatography
Inventor: HEARN MILTON THOMAS WILLIAM
IPC: C08G65/32
Filed: 2002-11-12
Granted: 2009-09-17
Abstract: The invention relates to a histidine-containing oligopeptide comprising an amino acid sequence selected from the group consisting of: HHHNSWDHDINR (SEQ. ID No. 1), HTNIHQDQHNHFHR (SEQ. ID No. 2), HAMLDRAHDHGTR (SEQ. ID No. 3), SLHEHHSGDNLR (SEQ. ID No. 4), THY-NAVHSHNTLQ (SEQ. ID No. 5), DIHHWTDHLQSSTH (SEQ. ID No. 6), and LYNHYSHTAHVNHL (SEQ. ID No. 7), a polypeptide which is a fusion protein comprising a protein molecule of interest fused at its amino terminus or carboxy terminus to said oligopeptide, a polypeptide obtainable by cultivating a host cell comprising a polynucleotide construct encoding said polypeptide in an appropriate growth medium under conditions allowing expression of said polypeptide and recovering said polypeptide from the culture medium, a polynucleotide construct encoding said polypeptide, a host cell comprising said polynucleotide construct and a method for producing said polypeptide.
Patent AU-2003214105-B2 (AU)
Title: Use of enzyme inhibitors with aminopeptidase N and/or dipeptidylpeptidase IV activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases with seborrhoeic hyperproliferation and altered differentiation states
Inventor: NEUBERT KLAUS
IPC: A61P17/10
Filed: 2003-03-07
Granted: 2008-11-13
Abstract: The invention relates to a process for the-inhibition of the DNA synthesis necessary for the proliferation of human sebaceous cells (sebocytes) by the isolated or joint effect of inhibitors of alanyl aminopeptidase (APN) and dipetidyl peptidase IV (DP IV) expressed by these cells. The DNA synthesis (proliferation) of human sebaceous cells is inhibited by the administration of the inhibitors of APN and/or of DP IV depending on the dose. Our invention shows that, for a therapy and for a prevention of dermatological diseases with sebaceous hyperproliferation and modified conditions of differentiation, the application of inhibitors of the above-mentioned enzymes and of corresponding pharmaceutical preparations and dosage forms thereof is suitable.